Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen, Inc. (Nasdaq: SRZN) is a biotechnology company developing Wnt pathway–modulating therapeutics with a focus on severe eye diseases, and its news flow reflects this ophthalmology and research orientation. Company press releases frequently highlight progress in its retinal disease pipeline, including updates on preclinical data for candidates such as SZN-8141, SZN-8143, and SZN-413, as well as plans related to regulatory milestones like an intended Investigational New Drug (IND) application for SZN-8141.
Investors following SRZN news can expect regular business updates tied to quarterly financial results, where Surrozen discusses research service revenue, operating expenses, and non-cash items alongside narrative commentary on pipeline momentum. These reports often describe how the company is leveraging its Wnt biology expertise and antibody technologies to advance programs in retinal vascular diseases.
Surrozen’s news stream also covers scientific and medical conference activity. The company reports presentations at ophthalmology-focused meetings such as the Association for Research in Vision and Ophthalmology (ARVO), Clinical Trials at the Summit, and various healthcare investor conferences. These announcements may include summaries of preclinical findings on Wnt-mediated retinal vascular repair and regeneration, as well as overviews of next-generation Wnt therapeutics in retinal diseases.
Corporate and governance developments are another recurring theme in SRZN news. Surrozen discloses leadership changes, including appointments to key roles like Chief Financial Officer and Vice President of Clinical Development, and reports inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Updates on intellectual property, such as the issuance of U.S. patents related to its SWAP™ technology for multi-specific Wnt surrogates, and collaboration developments, including changes to related-party research agreements and details of its partnership with Boehringer Ingelheim, also appear in its announcements. For readers tracking SRZN, this news page aggregates these financial, scientific, and corporate updates in one place.
Surrozen (Nasdaq: SRZN) will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 1:30 PM ET / 10:30 AM PT. Management will deliver a live presentation and audio webcast.
According to the company, the live audio webcast is available via the Investors section of Surrozen's website and a replay will be archived for at least 30 days.
Surrozen (Nasdaq: SRZN) said company management will present at two healthcare investor conferences in early December 2025: the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025 (fireside discussion at 6:30 AM PT / 9:30 AM ET) and the 8th Annual Evercore Healthcare Conference on December 3, 2025 (fireside chat at 12:25 PM PT / 3:25 PM ET).
Investors can access live audio webcasts and later replays via the Surrozen Investors website at https://investors.surrozen.com/events-presentations/events-calendar or archived at www.surrozen.com.
Surrozen (Nasdaq: SRZN) announced an inducement stock option grant to newly appointed CFO Andrew P. Maleki.
On November 6, 2025 the board approved options covering 50,000 shares under the company’s 2025 Equity Inducement Plan, exercisable at $12.94 per share (Nasdaq closing price on November 12, 2025). The options vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, subject to continuous service.
The awards were granted as an inducement material to acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Surrozen (Nasdaq: SRZN) reported third quarter 2025 results and a business update on Nov 7, 2025. Key clinical and corporate points: the company remains focused on its ophthalmology pipeline with lead candidates SZN-8141 and SZN-8143 and is on track to submit an IND for SZN-8141 in 2026. Leadership: Andrew Maleki joined as CFO; Charles Williams will continue as COO.
Q3 financials: cash $81.3M, collaboration revenue $0 (vs $10.0M in Q3 2024), R&D $7.8M, G&A $4.1M, net loss $71.6M or ($8.36) per share; noncash losses included $40.7M tranche liability and $20.9M other expense.
Surrozen (Nasdaq: SRZN) will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025. Management will hold a fireside chat at 6:30 AM Pacific Time / 9:30 AM Eastern Time. Interested parties can listen to the audio webcast via the Investors section of Surrozen's website and a replay will be archived at www.surrozen.com. The presentation covers company developments in targeted Wnt pathway therapeutics for severe eye diseases and is intended for investors and healthcare stakeholders.
Surrozen (Nasdaq: SRZN), a biotechnology company focused on Wnt pathway therapeutics for severe eye diseases, has granted inducement stock options to four new non-executive employees. The grants, approved on September 2, 2025, cover 45,710 shares of common stock at an exercise price of $12.32 per share.
The stock options were awarded under Surrozen's 2025 Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% vesting after the first year and the remainder vesting monthly thereafter, subject to continued employment.
Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics for severe eye diseases through Wnt pathway modulation, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for September 10, 2025, from 8:30 AM to 9:00 AM Pacific Time (11:30 AM to 12:00 PM Eastern Time). Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward.
Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics for the Wnt pathway with emphasis on severe eye diseases, has announced its participation in the Cantor Global Healthcare Conference 2025.
The company will participate in a fireside chat on September 4, 2025, from 8:00 - 8:30 AM Eastern Time. Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward at www.surrozen.com.
Surrozen (NASDAQ:SRZN), a biotechnology company focused on Wnt pathway therapeutics for eye diseases, reported Q2 2025 financial results and significant organizational developments. The company ended Q2 with $90.4 million in cash, down from $101.6 million in Q1, and posted net income of $39.7 million ($2.55 per share).
Key developments include the appointment of Dr. Daniel Chao as VP of Clinical Development, formation of a Clinical Advisory Board with leading retinal specialists, and receipt of a U.S. patent for their SWAP™ technology. The company's lead candidates, SZN-8141 and SZN-8143, continue progressing, with an IND submission for SZN-8141 planned for 2026.
Research revenue was $1.0 million, while R&D expenses increased to $6.0 million from $5.3 million year-over-year. The significant net income was primarily driven by non-cash gains from changes in fair value of tranche liability and warrant liabilities.
Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics that modulate the Wnt pathway for tissue repair and regeneration, particularly in severe eye diseases, has announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference.
The presentation will be available starting at 7:00 AM Eastern Time on Wednesday, August 13, 2025. Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward.
FAQ
What is the current stock price of Surrozen (SRZN)?
What is the market cap of Surrozen (SRZN)?
